CHARLES WYKOFF to Neovascularization, Pathologic
This is a "connection" page, showing publications CHARLES WYKOFF has written about Neovascularization, Pathologic.
Connection Strength
0.736
-
Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration. J Manag Care Spec Pharm. 2018 Feb; 24(2-a Suppl):S3-S15.
Score: 0.538
-
Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol. 2003 Feb 01; 21(3):473-82.
Score: 0.048
-
Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res. 2001 Nov 01; 61(21):7992-8.
Score: 0.044
-
Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res. 2001 Nov; 7(11):3399-403.
Score: 0.044
-
Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res. 2001 Jul 01; 61(13):5262-7.
Score: 0.043
-
DEC1 (STRA13) protein expression relates to hypoxia- inducible factor 1-alpha and carbonic anhydrase-9 overexpression in non-small cell lung cancer. J Pathol. 2003 Jun; 200(2):222-8.
Score: 0.012
-
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999 May 20; 399(6733):271-5.
Score: 0.009